ORIC Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	56.4	45.67	59.41	23.38	66.84	226.01
Short-Term Investments	225.54	235.82	196.55	184.8	139.43	10.97
Cash & Short-Term Investments	281.93	281.49	255.96	208.19	206.27	236.98
Cash Growth	38.39%	9.97%	22.95%	0.93%	-12.96%	-19.29%
Other Current Assets	8.3	6.98	6.29	4.41	4.19	3.54
Total Current Assets	290.23	288.47	262.25	212.6	210.46	240.52
Net Property, Plant & Equipment	2.15	2.42	-	2.86	3.25	2.41
Long-Term Investments	137.78	110.76	2.92	26.85	21.95	43.39
Other Long-Term Assets	6.6	7.25	8.97	9.7	11.52	12.32
Total Assets	436.76	408.89	274.14	252.01	247.18	298.64
Accounts Payable	2.9	3.82	1.55	0.94	1.32	1.89
Accrued Expenses	14.88	16.59	23.3	19.51	14.07	13.27
Total Current Liabilities	17.77	20.42	24.85	20.46	15.39	15.15
Other Long-Term Liabilities	3.43	4.11	6.17	7.46	9.44	10.52
Total Long-Term Liabilities	3.43	4.11	6.17	7.46	9.44	10.52
Total Liabilities	21.21	24.53	31.02	27.92	24.83	25.67
Common Stock	0.01	0.01	0.01	0.01	0.01	0
Additional Paid-in Capital	1,144	1,076	805.51	658.75	557.87	518.18
Accumulated Other Comprehensive Income	-0.29	0.79	0.38	0.26	-1.29	-0.1
Retained Earnings	-728.01	-692.24	-562.77	-434.93	-334.23	-245.11
Shareholders' Equity	415.56	384.36	243.12	224.09	222.35	272.98
Total Liabilities & Equity	436.76	408.89	274.14	252.01	247.18	298.64
Net Cash (Debt)	281.93	281.49	255.96	208.19	206.27	236.98
Net Cash Growth	0.16%	9.97%	22.95%	0.93%	-12.96%	-19.29%
Net Cash Per Share	2.93	3.21	3.67	4.05	5.20	6.24
Book Value	415.56	384.36	243.12	224.09	222.35	272.98
Book Value Per Share	4.32	4.38	3.49	4.36	5.61	7.19
Tangible Book Value	415.56	384.36	243.12	224.09	222.35	272.98
Tangible Book Value Per Share	4.32	4.38	3.49	4.36	5.61	7.19

SEC Filings: 10-K · 10-Q